# Biomarin Pharmaceutical Inc: overview

BMRN · Nasdaq · CIK 1048477 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bmrn.md) · [Financials](/companies/bmrn/financials.md) · [Filings](/companies/bmrn/filings.md) · [Insiders](/companies/bmrn/insiders.md)

Latest reported revenue: [$989.7m](/filings/0001048477-26-000016.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001048477-26-000016).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [746](/filings/0001048477-25-000107.md) | [747 d](/filings/0001048477-26-000004.md) | [745](/filings/0001048477-26-000008.md) | [825](/filings/0001048477-26-000016.md) | [776](/filings/0001048477-25-000107.md) | [875 d](/filings/0001048477-26-000004.md) | [766](/filings/0001048477-26-000008.md) | [990](/filings/0001048477-26-000016.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [15.3%](/filings/0001048477-25-000107.md) | [21.6% d](/filings/0001048477-26-000004.md) | [30.0%](/filings/0001048477-26-000008.md) | [33.5%](/filings/0001048477-26-000016.md) | [(6.0%)](/filings/0001048477-25-000107.md) | [(5.1%) d](/filings/0001048477-26-000004.md) | [16.9%](/filings/0001048477-26-000008.md) | [11.2%](/filings/0001048477-26-000016.md) |
| Net margin | % | [14.2%](/filings/0001048477-25-000107.md) | [16.7% d](/filings/0001048477-26-000004.md) | [24.9%](/filings/0001048477-26-000008.md) | [29.1%](/filings/0001048477-26-000016.md) | [(4.0%)](/filings/0001048477-25-000107.md) | [(5.3%) d](/filings/0001048477-26-000004.md) | [13.8%](/filings/0001048477-26-000008.md) | [4.5%](/filings/0001048477-26-000016.md) |
| Diluted EPS | $ per share | [0.55](/filings/0001048477-25-000107.md) | not reported | [0.95](/filings/0001048477-26-000008.md) | [1.23](/filings/0001048477-26-000016.md) | [(0.16)](/filings/0001048477-25-000107.md) | not reported | [0.54](/filings/0001048477-26-000008.md) | [0.23](/filings/0001048477-26-000016.md) |
| Free cash flow | $m | [203 d](/filings/0001048477-25-000107.md) | [166 d](/filings/0001048477-26-000004.md) | [158](/filings/0001048477-26-000008.md) | [168 d](/filings/0001048477-26-000016.md) | [340 d](/filings/0001048477-25-000107.md) | [58.9 d](/filings/0001048477-26-000004.md) | [200](/filings/0001048477-26-000008.md) | [139 d](/filings/0001048477-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,846](/filings/0001048477-24-000016.md) | [2,096](/filings/0001048477-25-000007.md) | [2,419](/filings/0001048477-26-000004.md) | [2,854](/filings/0001048477-26-000004.md) | [3,221](/filings/0001048477-26-000004.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(4.5%)](/filings/0001048477-24-000016.md) | [7.7%](/filings/0001048477-25-000007.md) | [7.7%](/filings/0001048477-26-000004.md) | [17.0%](/filings/0001048477-26-000004.md) | [12.7%](/filings/0001048477-26-000004.md) |
| Net margin | % | [(3.5%)](/filings/0001048477-24-000016.md) | [6.8%](/filings/0001048477-25-000007.md) | [6.9%](/filings/0001048477-26-000004.md) | [15.0%](/filings/0001048477-26-000004.md) | [10.8%](/filings/0001048477-26-000004.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001048477-24-000016.md) | [0.75](/filings/0001048477-25-000007.md) | [0.87](/filings/0001048477-26-000004.md) | [2.21](/filings/0001048477-26-000004.md) | [1.80](/filings/0001048477-26-000004.md) |
| Free cash flow | $m | [209](/filings/0001048477-24-000016.md) | [54.9](/filings/0001048477-25-000007.md) | [62.6](/filings/0001048477-26-000004.md) | [487](/filings/0001048477-26-000004.md) | [725](/filings/0001048477-26-000004.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bmrn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.17bn | 20,445,212 |  | Added +626,911 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $849.4m | 14,844,930 |  | Added +283,171 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $812.0m | 14,190,183 |  | Reduced −3,822 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $500.3m | 8,743,633 |  | Added +100,469 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $494.9m | 8,648,678 |  | Added +350,203 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $469.7m | 8,207,954 |  | New +8,207,954 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $446.4m | 7,800,959 |  | Added +505,880 |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $435.8m | 7,616,563 |  | Added +554,486 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $344.8m | 6,025,000 |  | Added +2,450,000 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $322.5m | 5,699,541 |  | Reduced −1,977,000 |

## Recent filings

[All 2,042 filings](/companies/bmrn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-06 | 20:22 ET | [8-K](/filings/0001048477-26-000019.md) | 2.02 Results of operations | 0001048477-26-000019 |
| 2026-09-30 | 20:15 ET | [8-K](/filings/0001628280-26-063981.md) | 1.01 Entry into a material agreement | 0001628280-26-063981 |
| 2026-09-15 | 12:31 ET | [8-K](/filings/0001628280-26-061973.md) | 8.01 Other events | 0001628280-26-061973 |
| 2026-09-14 | 13:26 ET | [8-K](/filings/0001628280-26-061717.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-061717 |
| 2026-09-01 | 13:23 ET | [8-K](/filings/0001193125-26-377696.md) | 8.01 Other events | 0001193125-26-377696 |
| 2026-08-31 | 10:01 ET | [8-K](/filings/0001193125-26-375275.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-375275 |
| 2026-08-18 | 12:39 ET | [8-K](/filings/0001193125-26-354780.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354780 |
| 2026-08-06 | 20:14 ET | [10-Q](/filings/0001048477-26-000016.md) | Quarterly report, period 2026-06-30 | 0001048477-26-000016 |
| 2026-08-06 | 20:06 ET | [8-K](/filings/0001048477-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001048477-26-000015 |
| 2026-07-13 | 20:06 ET | [8-K/A](/filings/0001048477-26-000011.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001048477-26-000011 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001048477-26-000004.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1048477
- Tickers: BMRN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.